ClinicalTrials.gg

TargetBeta

SLC5A2

solute carrier family 5 member 2 · also SGLT2 · Solute carrier family 5

6 programs in company-led studies act on SLC5A2, from 5 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
dapagliflozinAstraZenecaphase 413314 running–a judged reading
empagliflozinruleBoehringer Ingelheimphase 414210 running–NCIt
ertugliflozinruleMerckphase 4221 running–ChEMBL
EnavogliflozinruleDaewoong Pharmaceuticalphase 3258 running–the studies' text
vicadrostatBoehringer Ingelheimphase 3165 runningCYP11B2the company's pipeline
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 120 runningDPP4NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.